PA8506201A1 - COMBINATION CHEMOTHERAPY (COMBINATION CHEMOTHERAPY) - Google Patents

COMBINATION CHEMOTHERAPY (COMBINATION CHEMOTHERAPY)

Info

Publication number
PA8506201A1
PA8506201A1 PA20008506201A PA8506201A PA8506201A1 PA 8506201 A1 PA8506201 A1 PA 8506201A1 PA 20008506201 A PA20008506201 A PA 20008506201A PA 8506201 A PA8506201 A PA 8506201A PA 8506201 A1 PA8506201 A1 PA 8506201A1
Authority
PA
Panama
Prior art keywords
combination chemotherapy
combination
chemotherapy
acetildinaline
carboplatin
Prior art date
Application number
PA20008506201A
Other languages
Spanish (es)
Inventor
Ronald Lynn Merriman
Wayne Daniel Klohs
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8506201A1 publication Critical patent/PA8506201A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA ACETILDINALINA EN COMBINACION CON PACLITAXEL Y/O CARBOPLATINA ES SINERGISTICA PARA TRATAR EL CANCER.ACETILDINALINE IN COMBINATION WITH PACLITAXEL AND / OR CARBOPLATIN IS SYNERGISTIC TO TREAT CANCER.

PA20008506201A 1999-11-10 2000-11-09 COMBINATION CHEMOTHERAPY (COMBINATION CHEMOTHERAPY) PA8506201A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16488999P 1999-11-10 1999-11-10
US22256100P 2000-08-03 2000-08-03

Publications (1)

Publication Number Publication Date
PA8506201A1 true PA8506201A1 (en) 2002-12-11

Family

ID=26860956

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008506201A PA8506201A1 (en) 1999-11-10 2000-11-09 COMBINATION CHEMOTHERAPY (COMBINATION CHEMOTHERAPY)

Country Status (17)

Country Link
EP (1) EP1229916A2 (en)
JP (1) JP2003513912A (en)
KR (1) KR20020060226A (en)
CN (1) CN1387438A (en)
AR (1) AR026400A1 (en)
AU (1) AU1583201A (en)
CA (1) CA2386876A1 (en)
GT (1) GT200000194A (en)
HU (1) HUP0203153A3 (en)
IL (1) IL149363A0 (en)
NZ (1) NZ518668A (en)
PA (1) PA8506201A1 (en)
PE (1) PE20011028A1 (en)
PL (1) PL355170A1 (en)
SV (1) SV2001000212A (en)
UY (1) UY26431A1 (en)
WO (1) WO2001034131A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022216A3 (en) * 2001-07-02 2003-05-14 Warner-Lambert Company Compound chemotherapy
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
CA2552279C (en) * 2003-12-02 2014-07-15 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP2322217A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
PL2415382T3 (en) 2010-08-06 2013-02-28 Electrolux Home Products Corp Nv Table top dishwasher
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases

Also Published As

Publication number Publication date
WO2001034131A2 (en) 2001-05-17
AU1583201A (en) 2001-06-06
GT200000194A (en) 2002-05-03
HUP0203153A2 (en) 2003-01-28
CN1387438A (en) 2002-12-25
IL149363A0 (en) 2002-11-10
PL355170A1 (en) 2004-04-05
PE20011028A1 (en) 2001-10-12
UY26431A1 (en) 2000-12-29
EP1229916A2 (en) 2002-08-14
AR026400A1 (en) 2003-02-12
SV2001000212A (en) 2001-10-25
NZ518668A (en) 2004-04-30
KR20020060226A (en) 2002-07-16
WO2001034131A3 (en) 2002-05-10
JP2003513912A (en) 2003-04-15
HUP0203153A3 (en) 2005-01-28
CA2386876A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
UY28213A1 (en) NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS.
AR028296A1 (en) SYNERGISTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
FR2869231B1 (en) THERAPEUTIC COMPOSITION CONTAINING AT LEAST ONE PYRROLOBENZODIAZEPINE DERIVATIVE AND FLUDARABINE
TR200100859T2 (en) Cancer chemotherapy with acetildinal and gemcitabine, capecitabine or cisplatin combination
CR11486A (en) TREATMENT OF UTERINE CANCER AND OVARIO CANCER WITH A PARP INHIBITOR ONLY OR IN COMBINATION WITH ANTI-TUMOR AGENTS
PA8506201A1 (en) COMBINATION CHEMOTHERAPY (COMBINATION CHEMOTHERAPY)
AR044039A1 (en) ANTINEOPLASIC COMBINATIONS
BRPI0507463A (en) use of glufosfamide and gemcitabine, product, and, combination of glufosfamide and gemcitabine
NO20050640L (en) Ruthenium anticancer complexes
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
EA200200808A1 (en) MODIFIED CYTOKINES INTENDED FOR USE IN CANCER TREATMENT
BR0114430A (en) Processes for cancer cell death induction and tumor regression
ES2185323T3 (en) USE OF ERYTHROPOIETIN IN THE TREATMENT OF MULTIPLE MYELOMA.
DE602004014787D1 (en) ANTI-TUMORAL FORMULATIONS WITH DEFIBROTIDE ALONE OR IN COMBINATION WITH OTHER ANTITUMOROUS AGENTS
PT980205E (en) USE OF COMBINATION OF TALL-104 CELLS WITH ADRIAMYCIN OR CISPLATINE IN MALIGNANT TUMORS THERAPY
DK1135169T3 (en) Use of a pharmaceutical composition containing an anticancer agent and at least one peptide.
TR200302193T4 (en) Combination chemotherapy.
ECSP003755A (en) COMBINATION CHEMOTHERAPY
DOP2000000092A (en) COMBINATION CHEMOTHERAPY
AR029958A1 (en) USE OF STRAMUSTIN PHOSPHATE IN THE TREATMENT OF OSEA METASTASIS AND IN THE TREATMENT OF OSEA METASTASIS IN PATIENTS WITH PROSTATE CANCER
BRPI0417513A (en) chp-gemcitabine combined agents and their use as active antitumor substances
DE60134740D1 (en) COMPOSITION FOR POTENTIATING CANCER CHEMOTHERAPEUTIC
HK1048263A1 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides.
ECSP982458A (en) ORAL APPLICATION OF (+) - O- DEMETILTRAMADOL AS AN ANALGESIC
DOP2003000674A (en) THERAPEUTIC COMBINATIONS OF ERB B QUINASA INHIBITORS AND ANTINEOOLASIC THERAPIES